MG
LGND icon

Mather Group’s Ligand Pharmaceuticals LGND Stock Holding History

Mather Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1K Hold
130
– – ﹤0.01% 1150
2026
Q1 		$26K Buy
+130
New +$25.7K ﹤0.01% 1220
2025
Q4 		– Sell
-4
Closed -$709 – 1216
2025
Q3 		$709 Buy
+4
New +$595 ﹤0.01% 1606
2025
Q2 		– Sell
-4
Closed -$421 – 1242
2025
Q1 		$421 Hold
4
– – ﹤0.01% 1700
2024
Q4 		$429 Hold
4
– – ﹤0.01% 1671
2024
Q3 		$400 Sell
4
-24
-86% -$2.42K ﹤0.01% 1630
2024
Q2 		$2.05K Buy
28
+24
+600% +$1.91K ﹤0.01% 1884
2024
Q1 		$286 Buy
+4
New +$295 ﹤0.01% 1708

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mather Group's LGND Position: Q2 2026 in Review

Mather Group held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 130 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

Mather Group first reported a position in LGND in Q1 2024 and has held it in 8 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Mather Group held 130 shares of Ligand Pharmaceuticals worth $41.1K as of Q2 2026.
  • Mather Group left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1150 holding.
  • Mather Group first reported a position in Ligand Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.